Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 1997

View Archived Issues

Highlights of the 7th INWIN

Squalene synthase inhibitors from Takeda

Anti-H. pylori agents disclosed by Roussel Morishita

Orthosomycins discovered by Schering-Plough

Lilly describes new agents for postmenopausal syndrome

Chem. Pharm. Forschungs-Gesellschaft describes COX-2 inhibitors

MAO-A and/or MAO-B inhibitors described by Synthelabo

EAA antagonists reported by Pharmacia & Upjohn

5-HT reuptake inhibitors disclosed by NeuroSearch

Pyrimidine derivatives from Roche for psychotic disorders

Unfavorable phase III results of Bay-x-1351 reported

Potent, nonpeptide ECE-1/NEP inhibitor discovered by Novartis

Roche will acquire Boehringer Mannheim Group

Bexxar as first-line therapy for non-Hodgkin's lymphoma

Pfizer sponsors large cardiovascular trial in U.K. and Scandinavia

Panretin in AIDS-related Kaposi's sarcoma

MC-1288 + ciclosporin for allograft rejection

AMPA receptor antagonist YM-90K for acute ischemic stroke

Oral Kytril as effective as i.v. ondansetron for emesis

Xanomeline improves cognitive function and behavior in AD

Y-26763 protects against ischemia/reperfusion injury in dog model

Promising data from pivotal trials of Actiq reported at ASCO

ETA antagonist effective against neointima formation in rabbit model

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...